TELIX PHARMACEUTICALS LIMITED (TLX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

TLX - TELIX PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.3
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$22.20

21 Nov
2024

-0.760

OPEN

$22.97

-3.31%

HIGH

$23.22

1,072,563

LOW

$22.03

TARGET
$23.65 6.5% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
TLX: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 1.6 23.4 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A 100.0% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 96.5 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx1.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx502.5 M
Book Value Per Share xxxxxxxxxxxxxxx46.0
Net Operating Cash Flow xxxxxxxxxxxxxxx23.9 M
Net Profit Margin xxxxxxxxxxxxxxx1.04 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx4.55 %
Return on Invested Capital xxxxxxxxxxxxxxx4.09 %
Return on Assets xxxxxxxxxxxxxxx1.57 %
Return on Equity xxxxxxxxxxxxxxx4.55 %
Return on Total Capital xxxxxxxxxxxxxxx40.12 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx14.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx16 M
Total Debt xxxxxxxxxxxxxxx17 M
Goodwill - Gross xxxxxxxxxxxxxxx5 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx123 M
Price To Book Value xxxxxxxxxxxxxxx21.91

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx10.8 M
Capex % of Sales xxxxxxxxxxxxxxx2.15 %
Cost of Goods Sold xxxxxxxxxxxxxxx188 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx263 M
Research & Development xxxxxxxxxxxxxxx129 M
Investments - Total xxxxxxxxxxxxxxx12 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

18/07/2024

1

Buy

$26.00

17.12%

In a first impression by UBS of today's 2Q trading update by Telix Pharmaceuticals, the broker notes an around 11% beat against the consensus estimate for sales of the prostate cancer diagnostic.

Additionally, management's FY24 guidance was raised by 10% at the mid-point to between $745-776m when consensus was expecting $715m, according to the broker (which was predicting $781m).

New guidance implies to UBS sequential growth for Illuccix throughout the year, which is seen as possible given the rapid expansion in the market for PSMA PET scans.

Buy. Target $26.

FORECAST
UBS forecasts a full year FY24 dividend of 0.00 cents and EPS of 21.00 cents.
UBS forecasts a full year FY25 dividend of 0.00 cents and EPS of 28.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

02/09/2024

1

Buy

$22.59

1.76%

Telix Pharmaceuticals' 1H24 result showed an -18% miss on profit versus consensus once Jarden removes the US IPO costs and tax.

Isolating where the additional pre-tax costs came from in 1H24 is problematic, the broker notes, given the company has re-segmented and reallocated costs with no reconciliation to prior disclosures.

While costs are up, Jarden believes taking too strong a view against this increase versus expectations is short sighted considering the market's very limited knowledge of the cost structure of the businesses that have only recently been acquired.

Looking further out, the company is now in a very strong position in which its cash flow from operations can fund several R&D projects, the broker suggests.

Target rises to $22.59 from $22.55, Buy retained.

FORECAST
Jarden forecasts a full year FY24 dividend of 0.00 cents and EPS of 18.00 cents.
Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of 29.20 cents.

Taylor Collison

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

TLX STOCK CHART

FNArena News on TLX

1
Rudi’s View: The Importance Of ‘Quality’ Growth

Nov 21 2024 - Rudi's View
2
Rudi’s View: A Rally With No Earnings Support

Nov 14 2024 - Rudi's View
3
Australian Broker Call *Extra* Edition – Nov 12, 2024

Nov 12 2024 - Daily Market Reports
4
Rudi’s View: Trump Returns, What Now?

Nov 07 2024 - Rudi's View
5
Australian Broker Call *Extra* Edition – Nov 06, 2024

Nov 06 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps